Shares of ImmuPharma plc (LON:IMM – Get Free Report) were up 4.9% on Saturday . The stock traded as high as GBX 4.70 ($0.06) and last traded at GBX 3.67 ($0.04). Approximately 109,382,164 shares traded hands during mid-day trading, an increase of 245% from the average daily volume of 31,664,631 shares. The stock had previously closed at GBX 3.50 ($0.04).
ImmuPharma Stock Performance
The firm has a market capitalization of £15.30 million, a price-to-earnings ratio of -367.30 and a beta of 1.53. The stock’s fifty day moving average is GBX 1.44 and its two-hundred day moving average is GBX 1.65.
About ImmuPharma
ImmuPharma plc, a biopharmaceutical company, discovers and develops peptide-based therapeutics. Its peptide-based therapeutics are used in the therapy areas of autoimmunity and inflammation, and anti-infectives. The company's lead product candidate is the Lupuzor, an autophagy immunomodulator, which is in Phase III clinical trial for the treatment of lupus, an autoimmune chronic inflammatory disease.
Recommended Stories
- Five stocks we like better than ImmuPharma
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- ServiceTitan Made Waves in Its IPO, But Is the Stock a Buy?
- Low PE Growth Stocks: Unlocking Investment Opportunities
- Netflix: Is This the Perfect Time to Buy a Streaming Powerhouse?
- How is Compound Interest Calculated?
- Goldman Sachs Unveils 3 Massive Opportunities for 2025 Investors
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
